Mast cells elicit allergic responses through degranulation and release of proinflammatory mediators after antigen crosslinking of the immunoglobulin E receptor FceRI. Proteins of the 'regulator of G protein signaling' (RGS) family negatively control signaling mediated by G protein-coupled receptors through GTPase-accelerating protein activity. Here we show that RGS13 inhibited allergic responses by physically interacting with the regulatory p85a subunit of phosphatidylinositol-3-OH kinase in mast cells and disrupting its association with an FceRI-activated scaffolding complex. Rgs13 -/-mice had enhanced immunoglobulin E-mediated mast cell degranulation and anaphylaxis. Thus, RGS13 inhibits the assembly of immune receptor-induced signalosomes in mast cells. Abnormal RGS13 expression or function may contribute to disorders of amplified mast cell activity, such as idiopathic anaphylaxis.
Mast cells lie in close proximity to nerves and blood vessels in organs exposed to constant environmental challenge, such as the skin and the respiratory and gastrointestinal tract mucosa, which suggests a sentinel function in the innate immune response 1 . Mast cells also elicit allergic diseases such as asthma and anaphylaxis, accompanied by high titers of antigen-specific immunoglobulin E (IgE). In people who are allergic, antigen crosslinks IgE bound to its receptor, FceRI, on mast cells, eliciting the release of proinflammatory compounds such as histamine and the synthesis of leukotrienes and cytokines. Collectively, these mediators initiate type I hypersensitivity reactions characterized by increased vascular permeability, edema and smooth muscle contraction.
FceRI is a multiunit immune recognition receptor consisting of an a-chain and b-chain and two g-chains. The a-subunit binds IgE, whereas the b-and g-subunits transduce extracellular signals 2 . Crosslinking of FceRI by IgE-antigen induces the phosphorylation of immunoreceptor-based tyrosine activation motifs in the intracellular portions of the b-and g-chains by the tyrosine kinase Lyn, which attracts the kinase Syk to the g-chain. Tyrosine phosphorylation of Syk then propagates the signaling pathway through the recruitment and activation of phosphatidylinositol-3-OH kinase (PI(3)K), phospholipase C-g (PLC-g) and mitogen-activated protein kinase (MAPK). PI(3)K is essential to mast cell homeostasis and allergic responses 3 . Inactivation of p110d, the principal catalytic PI(3)K subunit in bone marrow-derived mast cells (BMMCs), severely impairs antigen-induced degranulation 4 . PI(3)K-mediated activation of PLC-g, which catalyzes the formation of inositol-1,4,5-trisphosphate, elicits an increase in the intracellular Ca 2+ concentration, leading to degranulation 5 .
Although allergic reactions have been attributed mainly to IgEmediated mast cell activation, G protein-coupled receptors (GPCRs) may amplify IgE-mediated responses 5 . Stimulation of adenosine (A 3 ) , chemokine, or prostaglandin (EP3) receptors accentuates mast cell degranulation induced by antigen [6] [7] [8] [9] . In contrast to FceRI, GPCRs catalyze GDP-GTP exchange on the a-subunit of a heterotrimeric G protein to activate a variety of effector pathways 10 . Signaling terminates through the intrinsic GTPase activity of the a-subunit, which converts Ga-GTP to Ga-GDP. Ga-GDP binds Gbg with high affinity, reconstituting the inactive heterotrimer.
Proteins of the 'regulator of G protein signaling' (RGS) family specify the durability and intensity of GPCR signaling through GTPase-accelerating protein (GAP) activity on Ga i and Ga q and antagonism of Ga effector interactions, which results in desensitization to continuous ligand exposure 11 . In mammalian cells, the RGS protein family includes more than 25 members that have an RGS domain of about 120 amino acids, which mediates direct binding to heterotrimeric G protein a-subunits, GAP activity and inhibition of G protein-mediated signaling 12 . RGS isoforms can be further categorized into subfamilies on the basis of additional protein-interaction motifs. However, members of the R4 subfamily of RGS proteins (RGS1-RGS5, RGS8, RGS13, RGS16, RGS18 and RGS21) have only short peptide sequences flanking the RGS domain. Despite extensive characterization of their biochemical actions in vitro, the physiological function of most R4 RGS proteins remains unknown.
Here we investigate R4 RGS proteins as potential regulators of allergic inflammation. We identify an unexpected function for RGS13 as a negative regulator of IgE-mediated mast cell degranulation and anaphylaxis that does not involve its GAP activity. RGS13 suppressed antigen-induced mast cell activation by binding the p85 subunit of PI(3)K and inhibiting protein-protein interactions in the FceRI signaling pathway.
RESULTS

Enrichment of RGS13 in mast cells
PCR and microarray analysis of various sources of mast cell RNA for R4 RGS family members showed expression of Rgs1, Rgs8, Rgs13, Rgs16 (ref. 13 ) and Rgs18 (Fig. 1a and data not shown). We confirmed RGS13 expression in BMMCs by immunofluorescence staining (Fig. 1b) . To study the function of RGS13 in mast cells, we generated Rgs13 -/-mice. We replaced exon 4 of Rgs13 with an in-frame lacZ cassette to use b-galactosidase activity as a surrogate for physiological RGS13 expression ( Supplementary Fig. 1 online) . Analysis of the b-galactosidase activity of Rgs13 -/-mice confirmed RGS13 expression in BMMCs and toluidine blue-positive mast cells in several organs, including skin, lung and conjunctiva ( Supplementary Fig. 2 online and data not shown).
RGS quantity may change rapidly in response to various stimuli, including GPCR ligands, and in some cases may impart feedback control 11, 14 . To delineate RGS13 content that might correlate with the regulation of specific mast cell receptors, we stimulated BMMCs with various compounds and measured Rgs13 mRNA abundance by quantitative real-time PCR. Whereas adenosine, complement component C5a and stem cell factor had little or no effect on Rgs13 expression, eotaxin decreased Rgs13 expression by nearly 50% (Fig. 1c and data not shown) . In contrast, antigen stimulation of BMMCs was accompanied by an increase of four-to fivefold in Rgs13 mRNA abundance after 24 h (Fig. 1c) . Prolonged antigen treatment of IgE-sensitized BMMCs also increased RGS13 protein (Fig. 1d) . Thus, antigen-elicited upregulation of RGS13 raised the possibility that this RGS protein may be involved in IgE-mediated mast cell responses.
RGS13 deficiency increases mast cell degranulation RGS13 deficiency did not affect the maturation or morphology of cultured BMMCs much; nor did it affect surface expression of FceRI ( Supplementary Figs. 2 and 3 online) . To determine whether RGS13 regulated mast cell activation, we compared the degranulation of mast cells from wild-type and Rgs13 -/-mice. Unexpectedly, we found that antigen-elicited degranulation by Rgs13 -/-BMMCs was significantly greater over a range of antigen concentrations (Fig. 2a) . In response to the optimal antigen concentration, Rgs13 -/-mast cells released nearly twice as much b-hexosaminidase as their wild-type counterparts did. The response of wild-type and Rgs13 -/-mast cells to the Ca 2+ ionophore ionomycin was similar, which excluded the possibility of a generalized abnormality of exocytosis (Fig. 2b) .
The potentiation of antigen-mediated degranulation may occur by autocrine secretion of GPCR ligands such as adenosine, resulting in activation of a Ga i -coupled signaling pathway 15 . To evaluate whether RGS13 GAP activity toward Ga i and inhibition of GPCR-mediated signaling contributed to its effect on antigen-induced degranulation, we preincubated cells with pertussis toxin (PTX) before antigen stimulation. PTX selectively inactivates members of the Ga i -Ga o family of G proteins 10 . PTX did not significantly affect antigeninduced degranulation of BMMCs (Fig. 2c) . In addition, antigenelicited degranulation of Rgs13 -/-BMMCs remained greater than that of wild-type BMMCs in the presence of PTX (Fig. 2c) . This finding indicated that the enhanced response of RGS13-deficient BMMCs to antigen did not involve Ga i . Furthermore, reconstitution of Rgs13 -/-BMMCs with recombinant fusion proteins of either wildtype RGS13 or mutant RGS13 with a substitution (Glu59Asn60 to Ala59Ala60) that eliminates RGS-Ga binding and GAP activity 16 , fused to the human immunodeficiency virus protein Tat (transactivator of transcription), inhibited the degranulation induced by IgE-antigen (Fig. 2d) . These results indicated that the enhanced degranulation of Rgs13 -/-BMMCs was due to the absence of RGS13 and that RGS13 inhibited IgE-mediated mast cell degranulation independently of its GAP activity.
Enhanced anaphylactic responses of Rgs13 -/-mice To evaluate mast cell degranulation in situ, we compared the passive cutaneous anaphylaxis of wild-type and Rgs13 -/-mice. Passive cutaneous anaphylaxis was almost twofold higher in Rgs13 -/-mice, as judged by visual inspection of the skin (Fig. 3a) and spectrophotometric quantification of Evans blue dye extracted from the reaction site (Fig. 3b) . Similarly, passive systemic anaphylaxis was enhanced in several organs of Rgs13 -/-mice ( Supplementary Fig. 4 online). Mast cell counts and morphology in several organs, including skin, were similar in Rgs13 -/-and wild-type mice ( Table 1 and Supplementary  Fig. 2) , Thus, the enhanced anaphylaxis of Rgs13 -/-mice was probably due to more mast cell degranulation rather than more tissue mast cells.
RGS13 interacts with PI(3)K
These results reported above collectively indicated that RGS13 might directly affect the FceRI signaling route, leading to mast cell degranulation. Given that tyrosinephosphorylation events are critical for antigen-elicited mast cell activation, we searched for RGS13-interacting proteins that might be responsible for its regulation of antigen-mediated signaling. For this, we incubated lysates of BMMCs with glutathione S-transferase-tagged RGS13 (GST-RGS13) and analyzed the precipitation reactions by immunoblot with antibody to phosphorylated tyrosine. GST-RGS13 'extracted' a tyrosine-phosphorylated protein doublet of about 80-85 kilodaltons (Fig. 4a) . Further analysis showed that one of these RGS13-associated proteins was the p85a regulatory subunit of PI(3)K. We also noted interaction of p85a with RGS13 in the rat basophilic leukemia cell line RBL-2H3, a mast cell line with more endogenous RGS13 than BMMCs have (Fig. 4b) .
FceRI stimulation activates class IA PI(3)K proteins consisting of dimers of p85a or p85b and p110a, p110b and p110d catalytic subunits 17 . Tyrosine phosphorylation of the adaptor protein Gab2 recruits p85 to the IgE receptor complex through a Src homology 2 domain in p85 (refs. 18,19) . Using recombinant proteins, we found that RGS13 directly bound p85a (Fig. 4c) . Although Src family kinases such as Lyn may phosphorylate tyrosine residues on p85a, the exact function of p85a tyrosine phosphorylation remains unclear 20, 21 . In this cell-free system, p85a tyrosine phosphorylation was required for binding to RGS13, as there was no interaction between the two proteins in the absence of p85a phosphorylation ( Supplementary  Fig. 5 online) . In contrast, RGS13 was not phosphorylated, which suggested that only p85a phosphorylation was required for formation of the RGS13-p85a complex. In addition, immunoprecipitation of endogenous p85a from lysates of antigen-stimulated BMMCs 'extracted' RGS13 (Fig. 4d) . Phosphorylation of p85a has been described in both unstimulated rat basophilic leukemia mast cells and BMMCs, which may account for constitutive PI(3)K activity in these cells 22, 23 . Although we detected interaction of RGS13 with p85a in unstimulated cells, this finding probably reflected basal phosphorylation of p85a. Our results collectively suggest that antigen stimulation increases the RGS13-p85a association. Finally, RGS13 did not affect antigen-induced p85a phosphorylation, as indicated by the similar p85a phosphorylation in wild-type and Rgs13 -/-BMMCs ( Supplementary Fig. 6 online).
RGS13 inhibits antigen-induced PI(3)K activation
We determined whether the binding of RGS13 to p85 regulated PI(3)K activity in mast cells. Consistent with the enhanced degranulation of Rgs13 -/-BMMCs, antigen-elicited production of phosphatidylinositol-3,4,5-triphosphate ( Fig. 5a ) and phosphorylation of the kinase Akt (Fig. 5b) were higher in these cells. Accordingly, events 'downstream' of PI(3)K signaling directly leading to degranulation, such as activation of PLC-g1 ( Fig. 5c ) and mobilization of intracellular Ca 2+ (Fig. 5d) , were also enhanced in the absence of RGS13. In contrast, Syk phosphorylation, one of the earliest events after receptor activation essential for antigen-induced mast cell degranulation 24 , was unchanged in Rgs13 -/-BMMCs, which indicated that RGS13 functions 'downstream' of receptor-dependent phosphorylation (Supplementary Fig. 7 online) . Activation of the MAPK Erk was also unaltered in Rgs13 -/-BMMCs ( Supplementary Fig. 7) . Consistent with the importance of MAPKs to cytokine synthesis in mast cells 5, 25 , antigen-stimulated cytokine production was similar in wild-type and Rgs13 -/-BMMCs ( Supplementary Fig. 8 online) .
We next studied the effect of RGS13 overexpression on PI(3)K activity in wild-type BMMCs. Transduction of BMMCs with Tat-RGS13 lead to an increase in RGS13 of more twofold relative to that of cells transduced with Tat-b-galactosidase (Fig. 6a) . In contrast to the enhanced FceRI-elicited Ca 2+ flux and PI(3)K activity associated with RGS13 deficiency, RGS13 expression inhibited antigen-induced Ca 2+ flux (Fig. 6b) and Akt phosphorylation (Fig. 6c) . Thus, RGS13 abundance substantially affects antigen-elicited PI(3)K activity and degranulation of mast cells.
Mechanism of PI(3)K inhibition by RGS13
To define the molecular mechanism whereby RGS13 regulated PI(3)K activity, we first determined the region in RGS13 that bound p85a. This interaction required only the amino-terminal 51 amino acids of RGS13, as a green fluorescent protein (GFP)-tagged construct of RGS13 containing only those 51 amino-terminal residues immunoprecipitated together with Myc-GFP-tagged p85a in human embryonic kidney (HEK293T) cells (Fig. 7a) . A Tat fusion protein of the construct of RGS13 containing only those 51 amino-terminal residues inhibited IgE-antigen-induced mast cell degranulation similar to wild-type RGS13 (Fig. 7b) . Neither of the Tat-RGS13 fusion proteins substantially inhibited the degranulation induced by ionomycin (data not shown). These studies indicated that the amino terminus of RGS13 mediates both the interaction with the p85a regulatory subunit of PI(3)K in mast cells and the inhibition of antigen-induced degranulation.
To further define how the RGS-p85a interaction affects PI(3)K function, we examined p85a protein-protein interactions after FceRI activation. Antigen crosslinking of the IgE receptor recruits tyrosine kinases such as Syk to the receptor complex to activate PI(3)K 18 . Phosphorylation of Gab2 by Syk recruits PI(3)K to a signaling scaffold that includes Grb2 and Gab2 (ref. 18 ). To evaluate the binding of p85a to the phosphorylated Gab2-containing complex, we first immunoprecipitated p85a from wild-type BMMCs transduced with Tat fusion proteins. Antibody to p85a (anti-p85a) coimmunoprecipitated Gab2 in BMMCs transduced with Tat-b-galactosidase, whereas transduction of cells with Tat-RGS13 impaired the formation of p85a-Gab2 complexes relative to that of control (Fig. 7c) . In a separate experiment, less p85a was coimmunoprecipitated by anti-Gab2 in antigen-stimulated wild-type BMMCs transduced with Tat-RGS13 than in cells transduced with Tat-b-galactosidase (Fig. 7d) .
The analysis reported above suggested that one mechanism whereby RGS13 regulates PI(3)K activity in mast cells might involve limiting the association of p85 with the FceRI-associated signaling complex; that is, by acting as a 'reverse' scaffolding protein. If this hypothesis were true, much more p85a would be associated with Gab2 in RGS13-deficient mast cells. To assess this possibility, we used GST-Grb2 beads, which were more efficient in 'extracting' Gab2-p85 complexes from BMMCs than was immunoprecipitation of either protein. Much more p85a was associated with GST-Grb2 in Rgs13 -/-BMMCs than in wildtype BMMCs (Fig. 7e) . The expression of p85a and p110d and the expression and phosphorylation of Gab2 were all unchanged in the absence of RGS13 (Fig. 7e) . These results collectively suggested that RGS13 affects the binding of p85a to an FceRI-associated signaling complex containing Gab2 and Grb2, which could contribute to the enhanced PI(3)K activity and degranulation of Rgs13 -/-mast cells ( Supplementary Fig. 9 online) . negative regulator of IgE-mediated mast cell reactivity was suggested by the greatly enhanced degranulation of Rgs13 -/-mast cells and anaphylaxis of Rgs13 -/-mice in response to antigen. RGS13 seemed to regulate mast cell degranulation by physically interacting with the p85a subunit of PI(3)K and impairing antigen-induced PI(3)K activation.
Several lines of evidence indicate that RGS13 directly inhibits PI(3)K signaling in mast cells independently of its GAP activity. RGS13 bound p85a directly, and the interaction required only the RGS13 amino terminus (amino acids 1-51), which does not have GAP activity (Z.X., E.N. Johnson and K.M.D., unpublished data). Amplification of mast cell degranulation by GPCR agonists such as adenosine occurs through activation of the PI(3)K-g isoform by Gbg released from Ga i -GTP 15 . PI(3)K-g does not associate with p85 subunits 26 , which suggests that RGS13 would not regulate PI(3)K-g directly. In our study, inactivation of Ga i proteins by PTX did not reduce antigen-elicited BMMC degranulation or diminish the differential responses of wild-type and Rgs13 -/-BMMCs to antigen. Finally, a mutant RGS13 protein devoid of GAP activity inhibited antigen-elicited degranulation similar to wild-type RGS13.
Whereas antigen-induced degranulation was greater in Rgs13 -/-BMMCs, cytokine production by mast cells was not enhanced by the loss of RGS13. Antigen-elicited cytokine synthesis is controlled by the pathways of the transcription factors calcium-NFAT and NF-kB, in addition to MAPKs. Although antigen-elicited PLC-g phosphorylation and Ca 2+ release were greater in the absence of RGS13, Erk activation was not affected by RGS13 deficiency. Preliminary evidence has also suggested that neither phosphorylation of Jun kinase nor NF-kB activation was very different in wild-type or Rgs13 -/-BMMCs stimulated with antigen (data not shown). MAPKs are regulated by intracellular Ca 2+ concentration through the activation of PLC-g and diacylglycerol, which in turn activate protein kinase C. Notably, however, there are at least four isoforms of PKC identified in mast cells that may regulate MAPK activity both positively (PKC-b) 27 and negatively (PKC-d) 28 . MAPKs can be also be activated by pathways independently of PKC (and therefore Ca 2+ ) 29 .
For those reasons, enhanced antigen-elicited PLC-g activity and the resultant increase in Ca 2+ mobilization in Rgs13 -/-BMMCs could lead to increased degranulation without substantially affecting MAPK activation and cytokine synthesis. Dissociation of cytokine production and degranulation in BMMCs deficient in diacylglycerol kinase-z has been reported 30 . The release of b-hexosaminidase is about 50% lower in such BMMCs. In contrast, their production of interleukin 6 (IL-6) is enhanced in response to antigen stimulation. In such cells, less antigen-elicited Ca 2+ mobilization resulting in less recruitment of PKC-bII to the membrane may account for the suppressed degranulation, whereas enhanced activation of Erk and Akt might explain the greater IL-6 production.
In addition to MAPKs, Akt mediates antigen-induced cytokine production 31 . Ca 2+ -calmodulin has been shown to interact with the pleckstrin homology domain of Akt, which competes with phosphatidylinositol-3,4,5-triphosphate for binding to Akt 32 . Calmodulin inhibits recruitment of Akt to the membrane and impairs its subsequent activation. Several members of the R4 subfamily of RGS proteins interact with calmodulin through a conserved motif in the RGS domain 33, 34 . As RGS13 contains this sequence, the absence of RGS13 in BMMCs could result in the availability of more calmodulin to inhibit Akt, thus counterbalancing the higher PI(3)K catalytic activity. Such results collectively suggest that RGS13 might be more important in regulating type I immediate hypersensitivity reactions than the innate immune functions of mast cells involving cytokine synthesis and release.
It is believed that whereas cytosolic p85a-p110 complexes are catalytically inactive, recruitment of Src homology 2 domains in p85 subunits to phosphorylated tyrosine residues in receptors or adaptor proteins activates PI(3)K by positioning the p110 subunit in proximity to membrane lipid substrates 26 . Notably, deletion of the p85a isoform resulted in only minor defects in the IgE-mediated degranulation of BMMCs, whereas RGS13 deficiency profoundly affected degranulation and anaphylaxis. We attribute this discrepancy to the fact that the p85b isoform, whose expression is upregulated in p85a-knockout mast cells 35 , may compensate for the loss of p85a in p85a-knockout cells. In contrast, RGS13 may bind more than one p85 isoform. The larger amount of p85a bound to Gab2 in Rgs13 -/-mast cells suggested that RGS13 inhibits PI(3)K activity by restricting the accessibility of p85 to its FceRI-associated scaffolding complex after receptor stimulation, resulting in diminished antigen-induced mast cell degranulation.
The binding of RGS13 to p85a and inhibition of PI (3)K signaling required only the 51 amino-terminal amino acids of RGS13. Studies have suggested the amino terminus of several R4 RGS proteins, which adopts an a-helical conformation in vivo 36 but is disordered in the crystal structure of recombinant RGS4 in complex with Ga i1 (ref. 37) , may act together with diverse signaling molecules to integrate pathways elicited by various cell surface receptors 38 . Such interactions have been proposed to stabilize the amino terminus of RGS proteins in distinct conformations depending on the binding partner 38 . For example, some RGS proteins may selectively regulate a subset of GPCRs by binding additional proteins such as spinophilin 39, 40 or the third intracellular loop of the receptor itself 41 .
RGS13 is also expressed in human and mouse B lymphocytes. Staining of b-galactosidase in 'lacZ-knock-in' mice indicated that RGS13 indeed has very limited tissue expression, restricted to lymphocytes, mast cells and endocrine cells of the thymus, gastrointestinal and respiratory tracts. Thus, the enhanced allergic responses of Rgs13 -/-mice were probably not due to enhanced vascular permeability induced by mast cell vasoactive mediators on end-organ targets. This explanation could account for the observed phenotype if, for example, endothelial cells had high expression of RGS13 and loss of RGS13 expression in such cells increased signaling to GPCR agonists such as histamine. We did detect binding of other R4 RGS proteins, including RGS1, RGS4, RGS5 and RGS16, to p85a, which suggested that this interaction was common to this subfamily of RGS proteins (data not shown). As RGS1 and RGS13 are abundant in B cells 42, 43 and RGS16 is enriched in activated T cells 44, 45 , RGS proteins may regulate PI(3)K activation elicited by antigen receptors in lymphocytes, which could have a substantial effect on other adaptive immune responses.
In B lymphocytes, RGS13 is induced by stimulation with anti-CD40 and IL-4 (ref. 43 ). Here we found that RGS13 in mast cells was upregulated by antigen stimulation. RGS13 abundance is also greater in human basophils treated with IgE-antigen 46 . Thus, antigen-induced expression of RGS13 could potentially restrict or prevent tissue damage from continual mast cell degranulation due to recurring antigen exposure, which may occur in beekeepers or in patients with allergies who are undergoing immunotherapy. Conversely, loss of RGS function due to lower expression or inactivating mutation(s) could underlie or contribute to the pathogenesis of disorders characterized by greater mast cell degranulation, such as idiopathic anaphylaxis.
In summary, here we have elucidated a new link between GPCR signaling pathways and the mainly tyrosine-dependent signaling elicited by immune receptor activation in mast cells. Regulation of PI(3)K activity by RGS13 resulted in increased mast cell degranulation and allergic responses. Given the ubiquity of RGS proteins, the evidence presented here for the direct mitigation of PI(3)K signaling by an R4 RGS family member indicates a common mechanism by which cells integrate or specify diverse and/or conflicting extracellular cues. As PI(3)K is critical in biological processes such as glucose metabolism and cancer progression, investigation of the regulation of PI(3)K signaling by RGS proteins in other systems is warranted, given the results of our study here.
METHODS
Rgs13 -/-mice. Rgs13 -/-mice were generated by targeting of exon 4 and replacement with an in-frame lacZ cassette. Age-matched littermates 4-10 weeks old were used for all experiments (targeting strategy and further characterization of mice, Supplementary Fig. 1 online) . All animal experiments were approved by and done in accordance with the Animal Care and Use Committee of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
Immunohistochemistry and immunofluorescence. BMMCs were spread onto glass coverslips by 'cytospin' and were stained with polyclonal anti-RGS13 (ref. 43) and Texas Red-conjugated anti-rabbit IgG (TI1000; Vector Labs). Acid toluidine blue counterstaining was used to locate tissue mast cells, and staining with DAPI (4¢-6-diamidino-2-phenylindole; Sigma) identified nuclei.
Quantitative analysis of RGS13 expression. Rgs13 mRNA in BMMCs stimulated with various agonists was evaluated by real-time quantitative PCR with Platinum SYBR Green qPCR SuperMix-UDG according to the manufacturer's instructions (Invitrogen). The primers were as follows: Rgs13, 5¢-GAAAAT TGCTTCACGAAGGGG-3¢ and 5¢-GCATGTTTGAGTGGGTTCACGAATG-3¢; and Gapdh (encoding glyceraldehyde phosphate dehydrogenase), 5¢-AAC GACCCCTTCATTGAC-3¢ and 5¢-TCCACGACATACTCAGCAC-3¢. Rgs13 values were normalized to Gapdh values. Eotaxin was from Peprotech.
Mouse mast cell cultures. All in vitro studies used BMMCs extracted from femurs and cultured for 4-10 weeks in RPMI medium plus 10% (vol/vol) FBS (Gibco) and IL-3 (30 ng/ml; Peprotech). Flow cytometry for FceRI was done at 4-8 weeks with IgE monoclonal anti-dinitrophenyl (anti-DNP; SPE-7; Sigma) and fluorescein isothiocyanate-conjugated rat monoclonal anti-mouse IgE (R35-72; BD Biosciences). Cell purity was routinely over 95%.
Degranulation and calcium measurement. Release of b-hexosaminidase was measured as described 47 . Cells were grown for 12 h overnight in the absence of IL-3 with IgE anti-DNP (100 ng/ml) before being washed in Tyrode's buffer and stimulated with DNP-human serum albumin (Sigma). Intracellular Ca 2+ concentrations were measured in 96-well plates in triplicate with the FLIPR Calcium 3 Assay kit and a FlexStation II automated fluorimeter (Molecular Devices). PTX was from Sigma.
Passive cutaneous and systemic anaphylaxis. The measurement of anaphylactic responses has been described 47, 48 .
Biochemical studies. BMMC stimulation, immunoblot analysis, GST precipitation and immunoprecipitation were done as described 18 . GST-Grb2 (Protein Data Bank accession code, CAG46740) coupled to glutathione-Sepharose was from Upstate Biotechnology, and GST-RGS13 (Protein Data Bank accession code, AAB 84000) was expressed in bacteria and was purified on glutathioneSepharose according to the manufacturer's instructions (GE Biosciences). Antibodies to the following were used: phosphorylated tyrosine (4G10; Chemicon), GFP (sc-8334), hemagglutinin (12CA5), Myc (9E10), p85 ('panreactive'; Z-8; sc-423), p85a (B-9; sc-1637), Gab2 (M-19; sc-9313), Syk (N-19; sc-1077), PLC-g1 (1249; sc-81), Erk1 (C-16; sc-93), p110d (H-219; sc-7176) and RGS13 (G-12; sc-48279; all from Santa Cruz Biotechnology); phosphorylated PLC-g1 (44-696G; Biosource); phosphorylated Erk1/2 (9101), Akt phosphorylated at Thr308 (9275), and Akt (9272; all from Cell Signaling); and RGS13 (chicken antibody; XW-7524; ProSci). Plasmids encoding GFP-RGS13 truncation mutants were constructed by PCR from pEGFP-RGS13. Plasmids encoding Myc-GFP-tagged PI(3)K-p85a and histidine-tagged PI(3)K-p110a were transfected into HEK293T cells together with GFP-RGS13 constructs using Lipofectamine 2000 (Invitrogen). Cells were processed in buffer containing 20 mM Tris, pH 7.5, 300 mM NaCl, 10 mM b-mercaptoethanol, 10% (vol/vol) glycerol, 1% (vol/vol) Triton X-100 and a protease-phosphatase inhibitor mix (Roche), followed by immunoprecipitation with anti-Myc. The abundance of phosphatidylinositol-3,4,5-triphosphate was determined by thin-layer chromatography as described 49 and was quantified with a Storm 860 PhosphorImager and ImageQuant software (Molecular Dynamics).
Transduction of BMMCs with Tat fusion proteins. Full-length untagged RGS13, GFP-RGS13, and the GFP-tagged construct of RGS13 containing only the 51 amino-terminal residues were subcloned in-frame into pTat-H 6 HA. Recombinant Tat proteins were expressed in Escherichia coli and were purified by nickel-affinity chromatography as described 50 . The QuikChange kit (Stratagene) was used for point mutagenesis. Tat fusion proteins were added directly to BMMC cultures 30 min before antigen stimulation.
Cytokine measurement. Cytokines in BMMC supernatants were analyzed with the Multiplex Luminex kit 24 h after antigen stimulation according to the manufacturer's instructions (Biosource).
Statistical analysis. SigmaPlot software was used to determine statistical significance evaluated by a paired Students t-test for two groups or analysis of variance (ANOVA) for multiple groups. P values of less than 0.05 were considered significant.
Note: Supplementary information is available on the Nature Immunology website.
